Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term

Prestige Consumer Healthcare (PBH) is highlighted by Zacks Investment Research as a compelling value stock, despite its #3 (Hold) Zacks Rank. The company exhibits a strong value proposition with a 'B' Value Style Score and 'B' VGM Score, underpinned by an attractive forward P/E ratio of 17. This assessment is further supported by a recent upward revision in fiscal 2026 earnings estimates to $4.76 per share, positioning PBH as a potential long-term consideration for value-focused portfolios.

Analysis

Prestige Consumer Healthcare (PBH) is positioned as a notable value stock despite its neutral Zacks #3 (Hold) rating. The company's appeal stems from its strong auxiliary scores, including a 'B' for its overall VGM Score and a 'B' for its Value Style Score, which is supported by a forward P/E ratio of 17, cited as attractive. The fundamental outlook is bolstered by a history of consistently beating earnings expectations, with an average positive surprise of 2.8%. Looking forward, one analyst has revised fiscal 2026 earnings estimates upwards within the last 60 days, with the Zacks Consensus Estimate now standing at $4.76 per share. While this specific report has a low market impact score, it frames PBH as a stable operator in the over-the-counter healthcare market with compelling valuation metrics for long-term, value-focused investors.

Key Decisions for Investors

• Value-oriented investors could consider PBH's valuation compelling, given its forward P/E of 17 and 'B' Value Score, making it a candidate for a long-term portfolio despite its neutral 'Hold' rating.
• It is prudent to monitor for a broader shift in analyst consensus or an upgrade in the Zacks Rank, as the current positive earnings outlook for fiscal 2026 is driven by only a single analyst's upward revision.
• Considering the company's consistent but modest average earnings surprise of 2.8%, PBH appears better suited for portfolios seeking stability and value rather than those targeting high-growth or significant near-term momentum.